Holen Sie sich die Stockscreener-App
11.48
4.46%
0.49
Handel nachbörslich:
11.48
Schlusskurs vom Vortag:
$10.99
Offen:
$11.07
24-Stunden-Volumen:
884.56K
Relative Volume:
1.45
Marktkapitalisierung:
$608.06M
Einnahmen:
$8.78M
Nettoeinkommen (Verlust:
$-104.70M
KGV:
-4.8439
EPS:
-2.37
Netto-Cashflow:
$-82.68M
1W Leistung:
+8.10%
1M Leistung:
+4.08%
6M Leistung:
-23.31%
1J Leistung:
+137.19%
1-Tages-Spanne:
$10.91
$11.73
1-Wochen-Bereich:
$9.72
$11.73
52-Wochen-Spanne:
$4.09
$17.58
Stoke Therapeutics Inc Stock (STOK) Company Profile
Firmenname
Stoke Therapeutics Inc
Sektor
Branche
Telefon
781-430-8200
Adresse
45 WIGGINS AVENUE, BEDFORD, MA
Vergleichen Sie STOK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
11.48 | 608.06M | 8.78M | -104.70M | -82.68M | -2.37 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-03-26 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-07-25 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Fortgesetzt | Canaccord Genuity | Buy |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-10-24 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Eingeleitet | Jefferies | Buy |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-11-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Eingeleitet | UBS | Neutral |
| 2021-05-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-12-11 | Bestätigt | Needham | Buy |
| 2020-10-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-29 | Eingeleitet | Needham | Buy |
| 2019-12-18 | Eingeleitet | Wedbush | Outperform |
| 2019-11-12 | Eingeleitet | BTIG Research | Buy |
| 2019-10-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Credit Suisse | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
What is Leerink Partnrs' Forecast for STOK FY2025 Earnings? - MarketBeat
FY2025 Earnings Estimate for STOK Issued By Leerink Partnrs - Defense World
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Trading 6.9% HigherWhat's Next? - MarketBeat
How to Take Advantage of moves in (STOK) - Stock Traders Daily
Stoke Therapeutics (NASDAQ:STOK) Trading Down 5.6%What's Next? - MarketBeat
The 13% return this week takes Stoke Therapeutics' (NASDAQ:STOK) shareholders one-year gains to 116% - Yahoo Finance
Stoke Therapeutics (NASDAQ:STOK) Trading Up 6.3%Here's What Happened - MarketBeat
Cantor Fitzgerald Forecasts STOK FY2025 Earnings - Defense World
Brokers Offer Predictions for STOK FY2025 Earnings - MarketBeat
Possible Signal As Stoke Therapeutics Insiders Sell US$523k In Stock - Simply Wall St
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now? - MSN
When the Price of (STOK) Talks, People Listen - Stock Traders Daily
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Acquired by Assenagon Asset Management S.A. - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 9.7%Time to Buy? - MarketBeat
Barclays PLC Raises Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Is Stoke Therapeutics Inc (NASDAQ: STOK) Still Trending? - Stocks Register
Head-To-Head Contrast: Inhibitor Therapeutics (OTCMKTS:INTI) and Stoke Therapeutics (NASDAQ:STOK) - Defense World
Q1 EPS Estimates for Stoke Therapeutics Raised by Wedbush - Defense World
Stoke Therapeutics Inc (STOK): Worth A Small Bite At $8.92 - Stocks Register
Wedbush Equities Analysts Raise Earnings Estimates for STOK - MarketBeat
What is Wedbush’s Estimate for STOK FY2029 Earnings? - Defense World
Research Analysts Offer Predictions for STOK FY2029 Earnings - MarketBeat
Learn to Evaluate (STOK) using the Charts - Stock Traders Daily
Stoke Therapeutics to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
Analyst maintains OW rating on Stoke Therapeutics as P3 EMPEROR study design finalized - Investing.com Canada
Needham & Company LLC Reiterates "Buy" Rating for Stoke Therapeutics (NASDAQ:STOK) - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Receives "Buy" Rating from HC Wainwright - MarketBeat
The Analyst Verdict: Stoke Therapeutics In The Eyes Of 4 Experts - Benzinga
Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results - Yahoo Finance
Stoke Therapeutics (NASDAQ:STOK) Shares Gap DownTime to Sell? - MarketBeat
Stoke Therapeutics Gains Regulatory Alignment for Phase 3 Study - TipRanks
STOKStoke Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Stoke Therapeutics aligns with regulators on Dravet study - Investing.com
Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome - Business Wire
Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome - Business Wire
Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Target Price at $21.29 - MarketBeat
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Franklin Resources Inc. Cuts Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Geode Capital Management LLC Boosts Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
Geode Capital Management LLC Buys 76,661 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Barclays PLC Purchases 47,239 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock Holdings Lifted by Barclays PLC - MarketBeat
When (STOK) Moves Investors should Listen - Stock Traders Daily
Skorpios Trust Reduces Stake in Stoke Therapeutics Inc - GuruFocus.com
Stoke therapeutics sees $23 million stock sale by Skorpios Trust - Investing.com Canada
The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex - Yahoo Finance
Stoke Therapeutics (NASDAQ:STOK) Trading Down 2.9%Should You Sell? - MarketBeat
Finanzdaten der Stoke Therapeutics Inc-Aktie (STOK)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):